What is the difference between CagriSema and Dulaglutide?

CagriSema: CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study. Dulaglutide: Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take CagriSema and Dulaglutide together?

There is no specific, well-documented interaction rule for combining CagriSema and Dulaglutide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, CagriSema or Dulaglutide?

CagriSema is currently investigational (in trials) and Dulaglutide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

CagriSema vs Dulaglutide

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CagriSema

Investigational (in trials)

CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.

Full profile

Dulaglutide

FDA-approved

Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.

Full profile

	CagriSema	Dulaglutide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination	Trulicity, LY2189265
Evidence	Investigational (in trials)	FDA-approved
Dosing range	0.25mg–2.4mg mg, once weekly subcutaneous (each component 2.4mg at target)	0.75mg–4.5mg mg, once weekly subcutaneous
Administration	Subcutaneous injection (weekly)	Subcutaneous injection (auto-injector pen)
Key side effects	Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite	Nausea (most common), Diarrhea, Vomiting, Abdominal pain
Cited sources	2 references	2 references

Key differences

Evidence level differs: CagriSema is investigational (in trials), while Dulaglutide is fda-approved.
Administration: CagriSema — Subcutaneous injection (weekly); Dulaglutide — Subcutaneous injection (auto-injector pen).
Frequency: CagriSema is typically once weekly subcutaneous (each component 2.4mg at target); Dulaglutide is once weekly subcutaneous.

How each works

CagriSema

CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.

Dulaglutide

Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.

Read the full CagriSema profile Read the full Dulaglutide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.